| Literature DB >> 34647149 |
Axel Wihlborg1,2, Karin Bergström3, Paul Gerdhem4,5, Ingrid Bergström4,6.
Abstract
BACKGROUND: Primary hyperparathyroidism (PHPT) is a common endocrine disorder with a wide range of adverse effects, such as osteoporosis. Many women are not diagnosed due to asymptomatic disease or vague symptoms but are still at risk of severe adverse effects. Early identification of patients with PHPT is therefore of importance. The aim of this study was to determine PHPT prevalence among postmenopausal women with a distal forearm fracture.Entities:
Mesh:
Substances:
Year: 2021 PMID: 34647149 PMCID: PMC8677684 DOI: 10.1007/s00268-021-06331-w
Source DB: PubMed Journal: World J Surg ISSN: 0364-2313 Impact factor: 3.352
Fig. 1Flowchart of the screening and follow-up procedure. The 2nd blood sample included a full clinical evaluation. A total of 11 women were diagnosed with PHPT after the 2nd and 3rd samples. PHPT = Primary hyperparathyroidism. a Declined or no follow-up available. b No further follow-up indicated. c Already diagnosed with PHPT at the time of fracture
Fig. 2Distribution at screening of the 161 women with a distal forearm fracture. a Serum calcium corrected for serum albumin (mmol/L). b Ionized calcium (mmol/L)
Biochemical profile of the 11 women diagnosed with PHPT. Serum calcium corrected for serum albumin. 25-hydroxy vitamin D (25OHD) was assessed separately from plasma stored at screening. PTH and serum calcium at screening were assessed from the supplementary samples in patients no 4–6 and 9. Mean time to 2nd sample: 4.4 (3.2) months and 3rd sample: 5.9 (3.7) months. Reference range: serum calcium (2.15–2.50 mmol/L), ionized calcium (1.15–1.33 mmol/L), phosphate (0.80–1.50 mmol/L), PTH (10–65 ng/L). NA = not available. Ca = calcium. PTH = parathyroid hormone
| Patient | Age | 1st sample (Screening at fracture) | 2nd sample | 3rd sample | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Serum Ca | Ionized Ca | PTH | Phosphate | 25OHD | Serum Ca | Ionized Ca | PTH | Serum Ca | Ionized Ca | PTH | |||
| nmol/L | |||||||||||||
| 1 | 60 | 2.54 | 1.43 | 76 | 0.75 | 71 | 2.61 | 1.46 | NA | 2.60A | 1.43 | 71 | |
| 2 | 71 | 2.47 | 1.28 | 204 | 0.95 | 59 | 2.66 | 1.44 | 191 | 2.84 | 1.52 | NA | |
| 3 | 57 | 2.37 | 1.34 | 104 | 0.70 | 57 | 2.50 | 1.35 | 58 | 2.52 | 1.37 | 82 | |
| 4 | 77 | 2.55 | 1.35 | 77 | 0.87 | 47 | 2.58 | 1.39 | 81 | 2.51 | 1.34 | 89 | |
| 5 | 61 | 2.67 | 1.36 | 113 | 0.73 | 56 | 2.51 | 1.40 | 91 | 2.54 | 1.42 | 104 | |
| 6 | 69 | 2.64 | 1.37 | 78 | 0.92 | 56 | 2.44 | 1.40 | 91 | 2.41 | 1.40 | 88 | |
| 7 | 57 | 2.49 | 1.29 | 70 | 0.82 | 67 | 2.37 | 1.28 | 67 | 2.68 | 1.29 | 59 | |
| 8 | 59 | 2.51 | 1.31 | 58 | 0.90 | 51 | 2.47 | 1.30 | 70 | 2.58A | 1.30 | 60 | |
| 9 | 50 | 2.53 | 1.37 | 53 | 0.94 | 85 | 2.46 | 1.42 | 72 | 2.23 | 1.34 | 62 | |
| 10 | 63 | 2.48 | 1.34 | 58 | 0.92 | 95 | 2.36 | 1.31 | 67 | 2.41A | 1.29 | 78 | |
| 11 | 62 | 2.46 | 1.30 | 48 | 0.89 | 52 | 2.41 | 1.31 | 72 | 2.49 | 1.28 | 70 | |
ASerum calcium not corrected for serum albumin
DXA results and clinical profiles of the 11 women with diagnosed PHPT. Clinical feature refers to the presence of symptoms such as fatigue, muscle weakness, joint pain, or depression. NA = not available
| Patient | Total hip | Femoral neck | L1-L2 | Osteoporosis | 33% of Radius | Clinical feature | Kidney stone | Clinical outcome | |
|---|---|---|---|---|---|---|---|---|---|
| 1 | − 1.1 | − 1.2 | − 2.4 | No | − 2.5 | Asymptomatic | No | Follow-up | |
| 2 | − 1.2 | − 1.7 | − 0.8 | No | − 1.4 | Symptomatic | No | Surgery | |
| 3 | − 2.2 | − 2.2 | − 2.3 | No | − 0.2 | Asymptomatic | No | Follow-up | |
| 4 | − 2.0 | − 2.4 | − 2.1 | No | − 1.3 | Asymptomatic | No | Follow-up | |
| 5 | − 1.1 | − 1.7 | − 0.8 | No | NA | Symptomatic | No | Surgery | |
| 6 | − 1.6 | − 1.8 | − 3.2 | Yes | − 5.0 | Symptomatic | Yes | Declined surgery (Follow-up) | |
| 7 | − 1.4 | − 2.4 | − 1.2 | No | − 0.6 | Asymptomatic | No | Follow-up | |
| 8 | − 1.9 | − 1.7 | − 1.6 | No | − 1.4 | Symptomatic | No | Declined surgery (Follow-up) | |
| 9 | − 0.9 | − 1.7 | 0.1 | No | − 0.5 | Asymptomatic | No | Follow-up | |
| 10 | − 0.9 | − 1.2 | − 1.9 | No | − 1.9 | Asymptomatic | No | Follow-up | |
| 11 | − 2.1 | − 2.1 | − 2.1 | No | − 3.2 | Symptomatic | No | Surgery |
Fig. 3Serum calcium corrected for serum albumin (mmol/L) and PTH (ng/L) at screening of the 11 women diagnosed with PHPT during follow-up. Arranged according to the biochemical definition of PHPT at screening. No criteria = did not meet any of the biochemical definitions of serum calcium and PTH at screening
List of reasons for PTH elevated above the reference range (> 65 ng/L) at screening
| Number of women | |
|---|---|
| Elevated PTH at screening (>65 ng/L) | 32 |
| PHPT | 9 |
| Vitamin D insufficiency <50 nmol/L | 15 |
| Vitamin D deficiency <25 nmol/L | 2 |
| Serum creatinine >90 μmol/L | 3 |
| Severe liver cirrhosis | 1 |
| Declined further follow-up | 2 |